Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases

Jun Nakashima, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Mototsugu Oya, Takashi Ohigashi, Masaru Murai

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: IL-6 has been reported to be a significant prognostic factor for prostate cancer and induces synthesis of C-reactive protein (CRP) by hepatocytes. The present study was undertaken to evaluate the clinical value of serum CRP in prostate cancer patients with metastases. Methods: The prognostic significance of serum CRP as well as tumor histology, extent of disease (EOD) on bone scan, serum levels of prostate-specific antigen (PSA) and alkaline phosphatase (ALP) and hemoglobin was assessed using Cox's proportional hazards model analyses in 126 prostate cancer patients with metastases treated with endocrine therapy. Results: Serum levels of CRP, PSA and ALP significantly increased and hemoglobin significantly decreased with advancing EOD grade. Univariate analysis demonstrated that EOD, CRP, PSA, ALP, hemoglobin and tumor histology are significantly associated with disease-specific survival. Multivariate analysis demonstrated that serum CRP and EOD were significant prognostic factors. The 5-year survival rates in low-risk patients (CRP ≤0.15 mg/dl and EOD ≤1) and high-risk patients (CRP >0.15 mg/dl and EOD ≥2) were 74 and 24%, respectively. Conclusion: These results indicate that a combination of serum CRP and EOD can identify patients with a poor prognosis who may be candidates for innovative treatments among prostate cancer patients with metastases.

Original languageEnglish
Pages (from-to)129-133
Number of pages5
JournalUrologia Internationalis
Volume80
Issue number2
DOIs
Publication statusPublished - 2008 Mar

Fingerprint

C-Reactive Protein
Blood Proteins
Prostatic Neoplasms
Neoplasm Metastasis
Bone and Bones
Survival
Prostate-Specific Antigen
Alkaline Phosphatase
Hemoglobins
Histology
Bone Diseases
Serum
Proportional Hazards Models
Hepatocytes
Interleukin-6
Neoplasms
Multivariate Analysis
Survival Rate
Therapeutics

Keywords

  • Endocrine therapy
  • Metastasis
  • Prognostic factors
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases. / Nakashima, Jun; Kikuchi, Eiji; Miyajima, Akira; Nakagawa, Ken; Oya, Mototsugu; Ohigashi, Takashi; Murai, Masaru.

In: Urologia Internationalis, Vol. 80, No. 2, 03.2008, p. 129-133.

Research output: Contribution to journalArticle

Nakashima, Jun ; Kikuchi, Eiji ; Miyajima, Akira ; Nakagawa, Ken ; Oya, Mototsugu ; Ohigashi, Takashi ; Murai, Masaru. / Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases. In: Urologia Internationalis. 2008 ; Vol. 80, No. 2. pp. 129-133.
@article{b0f5348adaef41838ae91dd678d973c7,
title = "Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases",
abstract = "Background: IL-6 has been reported to be a significant prognostic factor for prostate cancer and induces synthesis of C-reactive protein (CRP) by hepatocytes. The present study was undertaken to evaluate the clinical value of serum CRP in prostate cancer patients with metastases. Methods: The prognostic significance of serum CRP as well as tumor histology, extent of disease (EOD) on bone scan, serum levels of prostate-specific antigen (PSA) and alkaline phosphatase (ALP) and hemoglobin was assessed using Cox's proportional hazards model analyses in 126 prostate cancer patients with metastases treated with endocrine therapy. Results: Serum levels of CRP, PSA and ALP significantly increased and hemoglobin significantly decreased with advancing EOD grade. Univariate analysis demonstrated that EOD, CRP, PSA, ALP, hemoglobin and tumor histology are significantly associated with disease-specific survival. Multivariate analysis demonstrated that serum CRP and EOD were significant prognostic factors. The 5-year survival rates in low-risk patients (CRP ≤0.15 mg/dl and EOD ≤1) and high-risk patients (CRP >0.15 mg/dl and EOD ≥2) were 74 and 24{\%}, respectively. Conclusion: These results indicate that a combination of serum CRP and EOD can identify patients with a poor prognosis who may be candidates for innovative treatments among prostate cancer patients with metastases.",
keywords = "Endocrine therapy, Metastasis, Prognostic factors, Prostate cancer",
author = "Jun Nakashima and Eiji Kikuchi and Akira Miyajima and Ken Nakagawa and Mototsugu Oya and Takashi Ohigashi and Masaru Murai",
year = "2008",
month = "3",
doi = "10.1159/000112601",
language = "English",
volume = "80",
pages = "129--133",
journal = "Urologia Internationalis",
issn = "0042-1138",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases

AU - Nakashima, Jun

AU - Kikuchi, Eiji

AU - Miyajima, Akira

AU - Nakagawa, Ken

AU - Oya, Mototsugu

AU - Ohigashi, Takashi

AU - Murai, Masaru

PY - 2008/3

Y1 - 2008/3

N2 - Background: IL-6 has been reported to be a significant prognostic factor for prostate cancer and induces synthesis of C-reactive protein (CRP) by hepatocytes. The present study was undertaken to evaluate the clinical value of serum CRP in prostate cancer patients with metastases. Methods: The prognostic significance of serum CRP as well as tumor histology, extent of disease (EOD) on bone scan, serum levels of prostate-specific antigen (PSA) and alkaline phosphatase (ALP) and hemoglobin was assessed using Cox's proportional hazards model analyses in 126 prostate cancer patients with metastases treated with endocrine therapy. Results: Serum levels of CRP, PSA and ALP significantly increased and hemoglobin significantly decreased with advancing EOD grade. Univariate analysis demonstrated that EOD, CRP, PSA, ALP, hemoglobin and tumor histology are significantly associated with disease-specific survival. Multivariate analysis demonstrated that serum CRP and EOD were significant prognostic factors. The 5-year survival rates in low-risk patients (CRP ≤0.15 mg/dl and EOD ≤1) and high-risk patients (CRP >0.15 mg/dl and EOD ≥2) were 74 and 24%, respectively. Conclusion: These results indicate that a combination of serum CRP and EOD can identify patients with a poor prognosis who may be candidates for innovative treatments among prostate cancer patients with metastases.

AB - Background: IL-6 has been reported to be a significant prognostic factor for prostate cancer and induces synthesis of C-reactive protein (CRP) by hepatocytes. The present study was undertaken to evaluate the clinical value of serum CRP in prostate cancer patients with metastases. Methods: The prognostic significance of serum CRP as well as tumor histology, extent of disease (EOD) on bone scan, serum levels of prostate-specific antigen (PSA) and alkaline phosphatase (ALP) and hemoglobin was assessed using Cox's proportional hazards model analyses in 126 prostate cancer patients with metastases treated with endocrine therapy. Results: Serum levels of CRP, PSA and ALP significantly increased and hemoglobin significantly decreased with advancing EOD grade. Univariate analysis demonstrated that EOD, CRP, PSA, ALP, hemoglobin and tumor histology are significantly associated with disease-specific survival. Multivariate analysis demonstrated that serum CRP and EOD were significant prognostic factors. The 5-year survival rates in low-risk patients (CRP ≤0.15 mg/dl and EOD ≤1) and high-risk patients (CRP >0.15 mg/dl and EOD ≥2) were 74 and 24%, respectively. Conclusion: These results indicate that a combination of serum CRP and EOD can identify patients with a poor prognosis who may be candidates for innovative treatments among prostate cancer patients with metastases.

KW - Endocrine therapy

KW - Metastasis

KW - Prognostic factors

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=41149165635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149165635&partnerID=8YFLogxK

U2 - 10.1159/000112601

DO - 10.1159/000112601

M3 - Article

C2 - 18362480

AN - SCOPUS:41149165635

VL - 80

SP - 129

EP - 133

JO - Urologia Internationalis

JF - Urologia Internationalis

SN - 0042-1138

IS - 2

ER -